A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

ClinicalTrials.gov ID: NCT06765317

Public ClinicalTrials.gov record NCT06765317. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Optimizing Frontline Therapy for DLBCL in Older Adults: A GLOfitamab-based, Response-adapted, Window-stYle Study (GLORY)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The researchers are doing this study to find out if the study treatment is an effective treatment that causes few or mild side effects in people with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. The treatment being tested in this study is glofitamab, polatuzumab, and obinutuzumab in combination with standard treatment (the combination of rituximab, cyclophosphamide, doxorubicin, and prednisone, or R-miniCHP).

Study identification

NCT ID: NCT06765317
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Enrollment: 42 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 65 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 16, 2025 (Actual)
Primary completion: Jan 2028 (Estimated)
Completion: Jan 2028 (Estimated)
Last update posted: Jul 22, 2026

2025 – 2028

United States locations

U.S. sites: 8
U.S. states: 2
U.S. cities: 8

Facility	City	State	ZIP	Site status
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)	Basking Ridge	New Jersey	07920	Recruiting
Hackensack Meridian Health (Data collection only)	Hackensack	New Jersey	07601	Recruiting
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown	New Jersey	07748	Recruiting
Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale	New Jersey	07645	Recruiting
Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities)	Commack	New York	11725	Recruiting
Memorial Sloan Kettering Westchester (All Protocol Activities)	Harrison	New York	10604	Recruiting
Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York	New York	10065	Recruiting
Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Rockville Centre	New York	11553	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06765317, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 22, 2026 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06765317 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →